Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)

Patents Further Strengthen Global Intellectual Property Portfolio in Psychiatry NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare ...

2020-09-14 21:00 7073